David Toung

Bristol-Myers Squibb Co (NYSE: BMY)'s quest to expand its oncology franchise through its proposed acquisition of Celgene Corporation (NASDAQ: CELG) may not be a wise move, according to Argus. The Analyst David Toung downgraded Bristol-Myers Squibb from Buy to Hold, citing significant...

A sell-side analyst cited product supply and manufacturing issues, as well as sales declines, in a Friday downgrade of medical device maker Zimmer Biomet Holdings Inc (NYSE: ZBH). The Analyst  Argus analyst David Toung downgraded Zimmer Biomet from Buy to Hold. The Thesis Zimmer has ...

Celgene Corporation (NASDAQ: CELG) is down about 35 percent year-over-year, and as management resists challenges to critical Revlimid patents, analysts are at odds about where the stock could head from here. The Ratings Bernstein analyst Aaron Gal upgraded Celgene from Market-Perform to...

Cardinal Health Inc (NYSE: CAH) showed an improvement in gross margin in its fiscal second-quarter earnings report, and investors should have confidence in the company's ability to drive even more expansion, according to Argus. The Analyst Argus' David Toung upgraded...

Biogen Inc (NASDAQ: BIIB) tumbled 8 percent Wednesday after announcing a cohort expansion for its aducanumab Alzheimer’s trials — a change certain to delay results. The news, coupled with expected sales declines, has converted one analyst from an advocate to an observer. The Rating...

Amgen, Inc. (NASDAQ: AMGN) is likely to helped by both fundamental catalysts and the positive impact of the new U.S. tax law, an analyst said. The Analyst Argus analyst David Toung upgraded Amgen from Hold to Buy and set a price target of $220. In November, the firm had downgraded Amgen on...

If an 8-percent quarterly dividend increase is any indication, Eli Lilly and Co (NYSE: LLY) is confident of its growth potential. Its optimism echoes with one Wall Street analyst.  The Rating Argus analyst David Toung upgraded Eli Lilly from Hold to Buy with a $115 price target. The Thesis...

Shares of Allergan plc Ordinary Shares (NYSE: AGN) continue trading near their multi year low of $160.07, with many investors concerned with a competitive environment that will intensify in the coming years. The Analyst Argus' David Toung downgraded Allergan's stock rating from Buy to...

Cardinal Health Inc (NYSE: CAH) is seeing continued margin contraction at its Pharma Distribution segment. An analyst at Argus thinks this trend would continue, pressuring the stock. The Analyst & The Rating Argus analyst David Toung downgraded his rating on shares from Buy to Hold. The...

Biotech stocks are given to high volatility, given several risks confronting the sector, namely FDA decisions, clinical trial results, competitive pressure and drugs falling off patents. Gilead Sciences, Inc. (NASDAQ: GILD) — which has made a name for itself in the HIV and hepatitis C...

Argus downgraded shares of Amgen, Inc. (NASDAQ: AMGN), citing concerns about the secular slowdown in the sales of the company's top three products — namely Enbrel, Neulasta and Aranesp — which together accounted for 55 percent of the total revenues. As such, the firm downgraded...

It’s taking time, but three days after Gilead Sciences, Inc. (NASDAQ: GILD) announced its acquisition of Kite Pharma Inc (NASDAQ: KITE), the Street seems to be deciding it’s a good thing. Gilead’s stock traded up a modest 2.5 percent and three analysts reiterated Hold ratings...

Argus in a note released on Friday upgraded shares of Humana Inc (NYSE: HUM), with the upgrade premised on the belief that the company has strong growth prospects as an independent company following the termination of its merger agreement with Aetna Inc (NYSE: AET). The Annulled Deal Aetna...

Argus' David Toung downgraded shares of Celgene Corporation (NASDAQ: CELG) from Buy to Hold after fully digesting the company's first-quarter earnings report. Stay Critical, Investors According to Toung, investors have reason to be "concerned" over the company's revenue concentration from Revlimid...

Express Scripts Holding Company (NASDAQ: ESRX) reported robust fourth-quarter 2016 results. There are concerns, however, regarding Express Scripts’ customers wanting to lower prices at the time of contract renewal and the risk that the company’s largest customer Anthem Inc (NYSE: ANTM)...